Gene therapy targeting nuclear factor-κB: Towards clinical application in inflammatory diseases and cancer

Current Gene Therapy

Volumn 9, Issue 3, 2009, Pages 160-170

  Tas, Sander W ^a   Vervoordeldonk, Margriet J B M ^a,b   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Arthrogen BV   (Netherlands)

Author keywords

Adeno associated virus; Adenovirus; Adoptive transfer; Decoy oligodeoxynucleotides; Gene therapy; NF B; Signal transduction; SiRNA

Indexed keywords

ADENOVIRUS VECTOR; I KAPPA B ALPHA; I KAPPA B BETA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PARVOVIRUS VECTOR; SMALL INTERFERING RNA;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CACHEXIA; CANCER GENE THERAPY; DRUG SPECIFICITY; ENTERITIS; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSFER; GLOMERULONEPHRITIS; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SEPTIC SHOCK; SIGNAL TRANSDUCTION; STOMACH CANCER; TRANSCRIPTION INITIATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENE THERAPY; GENETICS; INFLAMMATION; METHODOLOGY; NEOPLASM;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE;

ANIMALS; GENE THERAPY; HUMANS; INFLAMMATION; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 70349575788     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309788488569     Document Type: Review

References (180)

1. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
2. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-62.
3. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388: 548-54.
4. Zandi E, Chen Y, Karin M. Direct phosphorylation of IkappaB by IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate. Science 1998; 281: 1360-63.
5. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998; 395: 297-300.
6. Yamaoka S, Courtois G, Bessia C, et al. Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. Cell 1998; 93: 1231-40.
7. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999; 189: 1839-45.
8. Senftleben U, Li ZW, Baud V, Karin M. IKKbeta is essential for protecting T cells from TNFalpha-induced apoptosis. Immunity 2001; 14: 217-30.
9. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 1999; 284: 321-25.
10. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 1999; 284: 309-13.
11. Chu WM, Ostertag D, Li ZW, et al. JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity 1999; 11: 721-31.
12. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999; 284: 316-20.
13. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495-99.
14. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-35.
15. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-24.
16. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-88.
17. Kinoshita D, Hirota F, Kaisho T, et al. Essential role of IkappaB kinase alpha in thymic organogenesis required for the establishment of self-tolerance. J Immunol 2006; 176: 3995-4002.
18. Takeda K, Takeuchi O, Tsujimura T, et al. Limb and skin abnormalities in mice lacking IKKalpha. Science 1999; 284: 313-16.
19. Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 2004; 428: 660-64.
20. Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 2001; 410: 710-14.
21. Li Q, Lu Q, Bottero V, et al. Enhanced NF-{kappa}B activation and cellular function in macrophages lacking I{kappa}B kinase 1 (IKK1). Proc Natl Acad Sci USA 2005; 102: 12425-30.
22. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138-43.
23. Lu LF, Gondek DC, Scott ZA, Noelle RJ. NF{kappa}B-inducing kinase deficiency results in the development of a subset of regulatory t cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation. J Immunol 2005; 175: 1651-57.
24. Tas SW, Vervoordeldonk MJ, Hajji N, et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood 2007; 110: 1540-49.
25. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13: 579-86.
26. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7: 817-23.
27. Grabiec AM, Tak PP, Reedquist KA. Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? Arthritis Res Ther 2008; 10: 226.
28. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002; 3: 224-29.
29. Ashburner BP, Westerheide SD, Baldwin AS, Jr. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001; 21: 7065-77.
30. Liu B, Yang Y, Chernishof V, et al. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity. Cell 2007; 129: 903-14.
31. Ghosh S, Hayden MS. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 2008; 8: 837-48.
32. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583-91.
33. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38: 1762-70.
34. Foxwell B, Browne K, Bondeson J, et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci USA 1998; 95: 8211-15.
35. Hiscott J, Marois J, Garoufalis J, et al. Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 1993; 13: 6231-40.
36. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-kappa B in human synovial cells in response to tumor necrosis factor alpha. Arthritis Rheum 1996; 39: 197-203.
37. Richmond A. Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2: 664-74.
38. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of I kappa B-alpha phosphorylation. J Immunol 1995; 155: 3538-45.
39. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 1995; 9: 899-909.
40. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum 2000; 43: 801-11.
41. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998; 28: 197-208.
42. Wang CY, Mayo MW, Baldwin AS, Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-87.
43. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274: 787-89.
44. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859-64.
45. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
46. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-83.
47. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135-142.
48. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289: 1550-54.
49. Gerlag DM, Ransone L, Tak PP, et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000; 165: 1652-58.
50. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kB activation induced by various carcinogens and inflammatory agents through inhibition of Ikappa Balpha kinase and p65 phosphorylation: Abrogation of cyclin D1, cyclooxygenase-2 and matrix metalloprotease-9. J Biol Chem 2004; 279: 4750-59.
51. Eckmann L, Nebelsiek T, Fingerle AA, et al. Opposing functions of IKKbeta during acute and chronic intestinal inflammation. Proc Natl Acad Sci USA 2008; 105: 15058-63.
52. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-1907.
53. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10: 617-24.
54. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IKK inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004; 279: 37219-22.
55. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48: 2652-59.
56. Tas SW, Remans PH, Reedquist KA, Tak PP. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 2005; 11: 581-611.
57. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, Pahan K. Anti-neuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 2004; 173: 1344-54.
58. Murata T, Shimada M, Sakakibara S, et al. Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. Bioorg Med Chem Lett 2003; 13: 913-18.
59. Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 2003; 13: 2419-22.
60. Liang MC, Bardhan S, Li C, Pace EA, Porco JA, Jr., Gilmore TD. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor kappaB by inhibiting the inhibitor of kappaB kinase. Mol Pharmacol 2003; 64: 123-31.
61. Kobori M, Yang Z, Gong D, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK Complex. Cell Death Differ 2004; 11: 123-30.
62. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
63. Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology (Oxford) 2006; 45: 656-68.
64. van de Loo FA, Smeets RL, van den Berg WB. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients? Arthritis Res Ther 2004; 6: 183-96.
65. Vervoordeldonk MJ, Aalbers C, Tak PP. Advances in local targeted gene therapy for arthritis: towards clinical reality. Future Rheumatol 2008; 3: 307-09.
66. Vilaboa N, Voellmy R. Regulatable gene expression systems for gene therapy. Curr Gene Ther 2006; 6: 421-38.
67. Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
68. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683-96.
69. Weber W, Fussenegger M. Pharmacologic transgene control systems for gene therapy. J Gene Med 2006; 8: 535-56.
70. Bessis N, GarciaCozar FJ, Boissier MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 2004; 11 (Suppl 1): S10-S17.
71. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-58.
72. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999; 286: 2244-45.
73. Tas SW, Hajji N, Stenvers DJ, Firestein GS, Vervoordeldonk MJ, Tak PP. Reduction of proinflammatory cytokine expression in the synovium by targeting IKKbeta in vivo in a rat model. Arthritis Rheum 2006; 54: 3716-18.
74. Oitzinger W, Hofer-Warbinek R, Schmid JA, Koshelnick Y, Binder BR, de Martin R. Adenovirus-mediated expression of a mutant IkappaB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. Blood 2001; 97: 1611-17.
75. Catley MC, Sukkar MB, Chung KF, et al. Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006; 70: 697-705.
76. Chapoval SP, Al Garawi A, Lora JM, et al. Inhibition of NF-kappaB activation reduces the tissue effects of transgenic IL-13. J Immunol 2007; 179: 7030-41.
77. Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006; 13: 21-31.
78. Karacay B, Sanlioglu S, Griffith TS, Sandler A, Bonthius DJ. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 2004; 11: 681-90.
79. Sanlioglu S, Luleci G, Thomas KW. Simultaneous inhibition of Rac1 and IKK pathways sensitizes lung cancer cells to TNFalpha-mediated apoptosis. Cancer Gene Ther 2001; 8: 897-905.
80. Zhou LF, Yin KS, Zhu ZL, et al. Adenovirus-mediated overexpression of novel mutated IkappaBalpha inhibits nuclear factor kappaB activation in endothelial cells. Chin Med J (Engl) 2005; 118: 1422-28.
81. Relic B, Bentires-Alj M, Ribbens C, et al. TNF-alpha protects human primary articular chondrocytes from nitric oxide-induced apoptosis via nuclear factor-kappaB. Lab Invest 2002; 82: 1661-72.
82. Wheeler MD, Yamashina S, Froh M, Rusyn I, Thurman RG. Adenoviral gene delivery can inactivate Kupffer cells: role of oxidants in NF-kappaB activation and cytokine production. J Leukoc Biol 2001; 69: 622-30.
83. Obara H, Takayanagi A, Hirahashi J, et al. Overexpression of truncated IkappaBalpha induces TNF-alpha-dependent apoptosis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20: 2198-2204.
84. Griesenbach U, Scheid P, Hillery E, et al. Anti-inflammatory gene therapy directed at the airway epithelium. Gene Ther 2000; 7: 306-13.
85. Taylor BS, Shao L, Gambotto A, Ganster RW, Geller DA. Inhibition of cytokine-induced nitric oxide synthase expression by gene transfer of adenoviral I kappa B alpha. Surgery 1999; 126: 142-47.
86. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 1998; 27: 1285-95.
87. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 1998; 160: 410-18.
88. Yang P, McKay BS, Allen JB, Roberts WL, Jaffe GJ. Effect of mutant IkappaB on cytokine-induced activation of NF-kappaB in cultured human RPE cells. Invest Ophthalmol Vis Sci 2003; 44: 1339-47.
89. Zhang HG, Huang N, Liu D, et al. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum 2000; 43: 1094-05.
90. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci USA 1999; 96: 5668-73.
91. Amos N, Lauder S, Evans A, Feldmann M, Bondeson J. Adenoviral gene transfer into osteoarthritis synovial cells using the endogenous inhibitor IkappaBalpha reveals that most, but not all, inflammatory and destructive mediators are NFkappaB dependent. Rheumatology (Oxford) 2006; 45: 1201-09.
92. Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol 2007; 34: 523-33.
93. Ishiyama T, Dharmarajan S, Hayama M, Moriya H, Grapperhaus K, Patterson GA. Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005; 130: 194-201.
94. Trescher K, Bernecker O, Fellner B, et al. Adenovirus-mediated overexpression of inhibitor kappa B-alpha attenuates postinfarct remodeling in the rat heart. Eur J Cardiothorac Surg 2004; 26: 960-67.
95. Suetsugu H, Iimuro Y, Uehara T, et al. Nuclear factor {kappa}B inactivation in the rat liver ameliorates short term total warm ischaemia/reperfusion injury. Gut 2005; 54: 835-42.
96. Takahashi Y, Ganster RW, Ishikawa T, et al. Protective role of NFkappaB in liver cold ischemia/reperfusion injury: effects of IkappaB gene therapy. Transplant Proc 2001; 33: 602.
97. Breuss JM, Cejna M, Bergmeister H, et al. Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 2002; 105: 633-38.
98. Bird MA, Black D, Lange PA, Samson CM, Hayden M, Behrns KE. NFkappaB inhibition decreases hepatocyte proliferation but does not alter apoptosis in obstructive jaundice. J Surg Res 2003; 114: 110-17.
99. Schreiber J, Efron PA, Park JE, Moldawer LL, Barbul A. Adenoviral gene transfer of an NF-kappaB super-repressor increases collagen deposition in rodent cutaneous wound healing. Surgery 2005; 138: 940-46.
100. Ni J, Takayama K, Ushijima R, et al. Adenovirus-mediated inhibitor kappaB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo. Anticancer Res 2008; 28: 601-08.
101. Ni J, Takayama K, Inoshima N, et al. Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo. Anticancer Res 2005; 25: 69-77.
102. Li TJ, Jia LP, Gao XL, Huang AL. Gene therapy that inhibits NFkappaB results in apoptosis of human hepatocarcinoma by recombinant adenovirus. World J Gastroenterol 2006; 12: 5287-92.
103. Tietze MK, Wuestefeld T, Paul Y, et al. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. Cancer Gene Ther 2000; 7: 1315-23.
104. Feig BW, Lu X, Hunt KK, et al. Inhibition of the transcription factor nuclear factor-kappa B by adenoviral-mediated expression of I kappa B alpha M results in tumor cell death. Surgery 1999; 126: 399-405.
105. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-17.
106. Bakker TR, Reed D, Renno T, Jongeneel CV. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int J Cancer 1999; 80: 320-23.
107. Mukogawa T, Koyama F, Tachibana M, et al. Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 2003; 94: 745-50.
108. Weaver KD, Yeyeodu S, Cusack JC, Jr., Baldwin AS, Jr., Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003; 61: 187-96.
109. Chen S, Fribley A, Wang CY. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor. J Dent Res 2002; 81: 98-102.
110. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr Gene Ther 2003; 3: 281-304.
111. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317: 477.
112. Niemeyer GP, Herzog RW, Mount J, et al. Long term correction of inhibitor prone hemophilia B dogs treated with liver-directed AAV2 mediated factor IX gene therapy. Blood 2009; 113: 797-806.
113. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adenoassociated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J Virol Methods 2007; 140: 183-92.
114. Ghivizzani SC, Gouze E, Gouze JN, et al. Perspectives on the use of gene therapy for chronic joint diseases. Curr Gene Ther 2008; 8: 273-86.
115. Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 2007; 318: 1535.
116. Adriaansen J, Tas SW, Klarenbeek PL, et al. Enhanced gene transfer to arthritic joints using adeno- associated virus type 5: implications for intra-articular gene therapy. Ann Rheum Dis 2005; 64: 1677-84.
117. Apparailly F, Khoury M, Vervoordeldonk MJ, et al. Adenoassociated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum Gene Ther 2005; 16: 426-34.
118. Tas SW, Adriaansen J, Hajji N, et al. Amelioration of arthritis by intra-articular dominant negative IKKbeta gene therapy using adeno-associated virus type 5. Hum Gene Ther 2006; 17: 821-32.
119. Squadrito F, Deodato B, Squadrito G, et al. Gene transfer of IkappaBalpha limits infarct size in a mouse model of myocardial ischemia-reperfusion injury. Lab Invest 2003; 83: 1097-1104.
120. Squadrito F, Deodato B, Bova A, et al. Crucial role of nuclear factor-kappaB in neointimal hyperplasia of the mouse carotid artery after interruption of blood flow. Atherosclerosis 2003; 166: 233-42.
121. Makarov SS, Johnston WN, Olsen JC, et al. NF-kappa B as a target for anti-inflammatory gene therapy: suppression of inflammatory responses in monocytic and stromal cells by stable gene transfer of I kappa B alpha cDNA. Gene Ther 1997; 4: 846-52.
122. Meunier A, Latremoliere A, Dominguez E, et al. Lentiviral-mediated targeted NF-kappaB blockade in dorsal spinal cord glia attenuates sciatic nerve injury-induced neuropathic pain in the rat. Mol Ther 2007; 15: 687-97.
123. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-99.
124. Isomura I, Morita A. Regulation of NF-kappaB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006; 50: 559-63.
125. Morishita R, Tomita N, Kaneda Y, Ogihara T. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides. Curr Opin Pharmacol 2004; 4: 139-46.
126. Ohtani K, Egashira K, Nakano K, et al. Stent-based local delivery of nuclear factor-kappaB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 2006; 114: 2773-79.
127. Egashira K, Suzuki J, Ito H, Aoki M, Isobe M, Morishita R. Longterm follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting. J Gene Med 2008; 10: 805-09.
128. Suzuki JI, Tezuka D, Morishita R, Isobe M. An initial case of suppressed restenosis with nuclear factor-kappa B decoy transfection after percutaneous coronary intervention. J Gene Med 2009; 11: 89-91.
129. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532-42.
130. Kunugiza Y, Tomita T, Tomita N, Morishita R, Yoshikawa H. Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo. Arthritis Res Ther 2006; 8: R103.
131. Tomita T, Takano H, Tomita N, et al. Transcription factor decoy for NFkappaB inhibits cytokine and adhesion molecule expressions in synovial cells derived from rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 749-57.
132. Shimizu H, Nakagami H, Tsukamoto I, et al. NFkappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 2006; 13: 933-41.
133. Desmet C, Gosset P, Pajak B, et al. Selective blockade of NFkappa B activity in airway immune cells inhibits the effector phase of experimental asthma. J Immunol 2004; 173: 5766-75.
134. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest 2005; 115: 3057-71.
135. De Vry CG, Prasad S, Komuves L, et al. Non-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut 2007; 56: 524-33.
136. Matsuda N, Hattori Y, Takahashi Y, et al. Therapeutic effect of in vivo transfection of transcription factor decoy to NF-kappaB on septic lung in mice. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1248-L1255.
137. Tomita N, Morishita R, Lan HY, et al. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000; 11: 1244-52.
138. Tomita N, Morishita R, Tomita S, et al. Transcription factor decoy for NFkappaB inhibits TNF-alpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 2000; 7: 1326-32.
139. D'Acquisto F, Ialenti A, Ianaro A, Di Vaio R, Carnuccio R. Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw. Gene Ther 2000; 7: 1731-37.
140. Nakamura H, Aoki M, Tamai K, et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002; 9: 1221-29.
141. Vos IH, Govers R, Grone HJ, et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14: 815-22.
142. Azuma H, Tomita N, Kaneda Y, et al. Transfection of NFkappaB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allografts. Gene Ther 2003; 10: 415-25.
143. Ohmori K, Takeda S, Miyoshi S, et al. Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg 2005; 27: 23-27.
144. Kawamura I, Morishita R, Tomita N, et al. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999; 6: 91-97.
145. Kawamura I, Morishita R, Tsujimoto S, et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 2001; 8: 905-12.
146. Azuma H, Tomita N, Sakamoto T, et al. Marked regression of liver metastasis by combined therapy of ultrasound-mediated NF kappaB-decoy transfer and transportal injection of paclitaxel, in mouse. Int J Cancer 2008; 122: 1645-56.
147. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
148. Fire AZ. Gene silencing by double-stranded RNA (Nobel Lecture). Angew Chem Int Ed Engl 2007; 46: 6966-84.
149. Mello CC. Return to the RNAi world: rethinking gene expression and evolution (Nobel Lecture). Angew Chem Int Ed Engl 2007; 46: 6985-94.
150. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-98.
151. Gewirtz AM. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 2007; 117: 3612-14.
152. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-22.
153. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007; 117: 3623-32.
154. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117: 3633-41.
155. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 2008; 19: 125-32.
156. Lee UJ, Choung SR, Prakash KV, et al. Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep 2008; 35: 291-98.
157. Lianxu C, Hongti J, Changlong Y. NF-kappaBp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1beta-induced and TNF-alpha-induced chondrocytes. Osteoarthritis Cartilage 2006; 14: 367-76.
158. Tian F, Zang WD, Hou WH, Liu HT, Xue LX. Nuclear factor-kB signaling pathway constitutively activated in esophageal squamous cell carcinoma cell lines and inhibition of growth of cells by small interfering RNA. Acta Biochim Biophys Sin (Shanghai) 2006; 38: 318-26.
159. Duan J, Friedman J, Nottingham L, Chen Z, Ara G, Van Waes C. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2007; 6: 37-50.
160. Lun M, Zhang PL, Pellitteri PK, Law A, Kennedy TL, Brown RE. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-kappaB. Ann Clin Lab Sci 2005; 35: 251-58.
161. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res 2004; 10: 3333-41.
162. Braun T, Carvalho G, Coquelle A, et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156-65.
163. Inoue M, Matsumoto S, Saito H, Tsujitani S, Ikeguchi M. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer. Int J Cancer 2008; 123: 2696-701.
164. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A. siRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 2008; 57: 2066-2073.
165. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-kappaBp65-specific siRNA. Osteoarthritis Cartilage 2008; 16: 174-84.
166. Pinkenburg O, Platz J, Beisswenger C, Vogelmeier C, Bals R. Inhibition of NF-kappaB mediated inflammation by siRNA expressed by recombinant adeno-associated virus. J Virol Methods 2004; 120: 119-22.
167. Mi J, Zhang X, Rabbani ZN, et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. Mol Ther 2008; 16: 66-73.
168. Gupta S, Young D, Maitra RK, et al. Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. J Mol Biol 2008; 375: 637-49.
169. van Duivenvoorde LM, Louis-Plence P, Apparailly F, et al. Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis Rheum 2004; 50: 3354-64.
170. Tarner IH, Slavin AJ, McBride J, et al. Treatment of autoimmune disease by adoptive cellular gene therapy. Ann N Y Acad Sci 2003; 998: 512-19.
171. Morita Y, Yang J, Gupta R, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-84.
172. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80.
173. Haniffa MA, Wang XN, Holtick U, et al. Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol 2007; 179: 1595-1604.
174. Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol 2003; 74: 438-47.
175. Tan PH, Sagoo P, Chan C, et al. Inhibition of NF-kappaB and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005; 174: 7633-44.
176. Tomasoni S, Aiello S, Cassis L, et al. Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells. Transplantation 2005; 79: 1056-61.
177. Aiello S, Cassis P, Cassis L, et al. DnIKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+. Transplantation 2007; 83: 474-84.
178. Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007; 178: 5480-87.
179. Bonham CA, Peng L, Liang X, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002; 169: 3382-91.
180. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 2005; 17: 170-74.